GANX Company Profile and Key Details

Q: Who are the executives of GANX?

Dr. Natalia Perez-Carmona Ph.D.Head of BiologyDr. Joanne Taylor Ph.D.Senior Vice President of Research & Scientific AdvisorDr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical OperationsDr. Xavier Barril Ph.D.Chief Technology OfficerDr. Manolo Bellotto Ph.D.GM & Chief Strategy OfficerDr. Ana Maria Garcia-Collazo Ph.D.Head of ResearchDr. Khalid Islam Ph.D.Founder & ChairmanMr. Salvatore CalabreseChief Financial Officer & Corporation Sec.Mr. Gianluca FuggettaPrincipal Accounting Officer & Senior Director of Corporation ReportingMr. Matthias Alder LIC. IUR., LL.M.Pres, Chief Executive Officer & DirectorMr. C. Evan BallantyneChief Financial Officer & Sec.

NASDAQ : GANX

Gain Therapeutics

$1.78

0.06+3.49%

At Close 4:00 PM

61.1

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Gain Therapeutics, Inc. (GANX) stock surged +3.49%, trading at $1.78 on NASDAQ, up from the previous close of $1.72. The stock opened at $1.76, fluctuating between $1.74 and $1.79 in the recent session.

Stock Snapshot

1.72

Prev. Close

75.92M

Market Cap

1.735

Day Low

-3.56

P/E Ratio

-0.5

EPS (TTM)

-1.17

Cash Flow per Share

1.76

Open

42.65M

Number of Shares

1.79

Day High

96.28%

Free Float in %

0.78

Book Value

340.03K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 17, 2026	1.76	1.79	1.74	1.78	340.03K
Sep 16, 2026	1.73	1.79	1.70	1.72	264.72K
Sep 15, 2026	1.74	1.74	1.69	1.71	215.69K
Sep 14, 2026	1.76	1.80	1.73	1.74	360.02K
Sep 11, 2026	1.75	1.78	1.72	1.75	223.49K
Sep 10, 2026	1.72	1.74	1.69	1.71	495.04K
Sep 09, 2026	1.81	1.83	1.72	1.72	512.67K
Sep 08, 2026	1.80	1.85	1.77	1.83	291.78K
Sep 04, 2026	1.81	1.83	1.79	1.80	200.86K
Sep 03, 2026	1.80	1.83	1.77	1.82	390.64K
Sep 02, 2026	1.78	1.85	1.75	1.79	365.09K
Sep 01, 2026	1.83	1.83	1.77	1.77	197.91K
Aug 31, 2026	1.77	1.84	1.76	1.80	259.44K
Aug 28, 2026	1.84	1.86	1.76	1.77	312.34K
Aug 27, 2026	1.85	1.90	1.80	1.85	415.61K
Aug 26, 2026	1.91	1.92	1.80	1.81	723.12K
Aug 25, 2026	2.00	2.05	1.90	1.91	383.15K
Aug 24, 2026	2.01	2.03	1.93	2.00	302.35K
Aug 21, 2026	2.00	2.05	1.98	2.01	277.46K
Aug 20, 2026	2.03	2.04	1.95	1.98	381.03K

Contact Details

Bethesda, MD 20814

United States

https://www.gaintherapeutics.com 301 500 1556

About Company

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

Stock Peers

ARGX

11.08001+1.13%

argenx SE$995.77 REGN

14.84+1.92%

Regeneron Pharmaceuticals, Inc.$789.45 MDGL

5.31+1.00%

Madrigal Pharmaceuticals, Inc.$534.40 VRTX

3.08+0.60%

Vertex Pharmaceuticals Incorporated$516.34 UTHR

-1.21-0.24%

United Therapeutics Corporation$497.27 ONC

5.38+1.55%

BeOne Medicines AG$353.46 KRYS

2.08001+0.62%

Krystal Biotech, Inc.$338.75 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

1.48+0.48%

Praxis Precision Medicines, Inc.$310.47 LGND

9.49999+3.45%

Ligand Pharmaceuticals Incorporated$284.70

Frequently Asked Questions

What is the current Gain Therapeutics, Inc. (GANX) stock price?

Gain Therapeutics, Inc. (NASDAQ: GANX) stock price is $1.78 in the last trading session. During the trading session, GANX stock reached the peak price of $1.79 while $1.74 was the lowest point it dropped to. The percentage change in GANX stock occurred in the recent session was 3.49% while the dollar amount for the price change in GANX stock was $0.06.

GANX's industry and sector of operation?

The NASDAQ listed GANX is part of Biotechnology industry that operates in the broader Healthcare sector. Gain Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GANX?

Dr. Natalia Perez-Carmona Ph.D.
Head of Biology
Dr. Joanne Taylor Ph.D.
Senior Vice President of Research & Scientific Advisor
Dr. Terenzio Ignoni Pharm.D.
Senior Vice President of Technical Operations
Dr. Xavier Barril Ph.D.
Chief Technology Officer
Dr. Manolo Bellotto Ph.D.
GM & Chief Strategy Officer
Dr. Ana Maria Garcia-Collazo Ph.D.
Head of Research
Dr. Khalid Islam Ph.D.
Founder & Chairman
Mr. Salvatore Calabrese
Chief Financial Officer & Corporation Sec.
Mr. Gianluca Fuggetta
Principal Accounting Officer & Senior Director of Corporation Reporting
Mr. Matthias Alder LIC. IUR., LL.M.
Pres, Chief Executive Officer & Director
Mr. C. Evan Ballantyne
Chief Financial Officer & Sec.

How GANX did perform over past 52-week?

GANX's closing price is 16.34% higher than its 52-week low of $1.53 where as its distance from 52-week high of $4.34 is -58.99%.

How many employees does GANX have?

Number of GANX employees currently stands at 21.

Link for GANX official website?

Official Website of GANX is: https://www.gaintherapeutics.com

How do I contact GANX?

GANX could be contacted at phone 301 500 1556 and can also be accessed through its website. GANX operates from 4800 Montgomery Lane, Bethesda, MD 20814, United States.

How many shares of GANX are traded daily?

GANX stock volume for the day was 340.03K shares. The average number of GANX shares traded daily for last 3 months was 766.42K.

What is the market cap of GANX currently?

The market value of GANX currently stands at $75.92M with its latest stock price at $1.78 and 42.65M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	21
Beta	0.21
Sales or Revenue	$55.18K
5Y Sales Change%	0.206%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	21
Beta	0.21
Sales or Revenue	$55.18K
5Y Sales Change%	0.206%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GANX Company Profile and Key Details

Gain Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics